Search - tctmd.com

Displaying 61 - 80 of 98

Sort: Relevancy | Date

News Daily News

Ticagrelor More Rapidly Suppresses Platelet Activity Than Clopidogrel for Low-Risk ACS Patients During Ad Hoc PCI

Todd Neale

May 11, 2015

Presentation

Ticagrelor vs Clopidogrel in Troponin-Negative ACS Patients Undergoing Ad Hoc PCI

Presenter: Roxana Mehran

May 08, 2015

News Industry News

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

May 07, 2015

News Daily News

元分析解释了不同DAPT时间长短的影响

Caitlin E. Cox

April 03, 2015

News Daily News

Un Meta Análisis Arrojan Luz sobre el Impacto de la Duración del Tratamiento Antiplaquetario Doble

Caitlin E. Cox

April 03, 2015

News Daily News

Meta-analyses Shed Light on the Impact of DAPT Duration

Caitlin E. Cox

April 03, 2015

Presentation TCT 2014

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Antonio Colombo

September 15, 2014

Presentation TCT 2014

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Nikolaus Sarafoff

September 15, 2014

Presentation TCT 2014

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

Presenter: Roxana Mehran, Harvey D. White, Yaling Han

September 15, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Roxana Mehran

September 14, 2014

Presentation TCT 2014

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Presenter: Roxana Mehran, Mohamed Sobhy

September 13, 2014

Presentation TCT 2014

Optimal Duration of DAPT After Intracoronary Stenting: Current Status

Presenter: Roxana Mehran

September 13, 2014

Presentation

Issues with DAPT: An Expert Case-Based Discussion

Presenter: Jonathan Halperin, Ajay Kirtane, Roxana Mehran

July 29, 2014

News Conference News EuroPCR 2014

PARIS Registry: Sex Disparity in DAPT Cessation Arises from Comorbidities

Yael L. Maxwell

May 21, 2014

News Daily News

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

May 14, 2014

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

News Daily News

HORIZONS-AMI: Mortality Reduction with Bivalirudin Only Partially Due to Bleeding

Caitlin E. Cox

November 01, 2013

News Daily News

HORIZONS-AMI：使用比伐卢定减少出血仅为死亡率降低的部分原因

Caitlin E. Cox

November 01, 2013

Presentation TCT 2013

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

Presenter: Roxana Mehran

October 31, 2013

Presentation TCT 2013

DES Implantation in a Patient with Atrial Fibrillation

Presenter: Roxana Mehran

October 31, 2013

Advertisement

Ticagrelor More Rapidly Suppresses Platelet Activity Than Clopidogrel for Low-Risk ACS Patients During Ad Hoc PCI

Ticagrelor vs Clopidogrel in Troponin-Negative ACS Patients Undergoing Ad Hoc PCI

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

元分析解释了不同DAPT时间长短的影响

Un Meta Análisis Arrojan Luz sobre el Impacto de la Duración del Tratamiento Antiplaquetario Doble

Meta-analyses Shed Light on the Impact of DAPT Duration

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

The Data Strongly Support Bivalirudin!

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Optimal Duration of DAPT After Intracoronary Stenting: Current Status

Issues with DAPT: An Expert Case-Based Discussion

PARIS Registry: Sex Disparity in DAPT Cessation Arises from Comorbidities

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

HORIZONS-AMI: Mortality Reduction with Bivalirudin Only Partially Due to Bleeding

HORIZONS-AMI：使用比伐卢定减少出血仅为死亡率降低的部分原因

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

DES Implantation in a Patient with Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content